Andrew Lloyd

Andrew Lloyd is a Lecturer in Medical Radiation Science within the School of Health Sciences at the University of Newcastle, Australia, specializing in Nuclear Medicine. With over 30 years of clinical experience as an accredited nuclear medicine technologist since 1992—including roles as Chief Technologist in Australia and London—he bridges academic instruction with active practice at Hunter and New England Imaging Service.

His educational background includes:

• Master of Public Health with Distinction (University of Newcastle)
• Diploma of Applied Science (University of Sydney)
• Graduate Certificate in Public Health (University of Newcastle)

Lloyd's research centers on PET/CT dose optimization and clinical technology implementation, particularly for 18F-FDG oncological imaging. He developed an image quality analysis tool with collaborators Andrew Chicco and Paul Cardew and investigates measured Glomerular Filtration Rate applications for chronic kidney disease. His work emphasizes practical clinical translation to enhance diagnostic protocols.

His 2014 publications analyze 18F-FDG dose guidelines for whole-body PET/CT, revealing significant gaps between current practices and optimal imaging standards across oncology applications.

Scientific recognition includes:

• 2001 Amersham Award for validating sequential scanning protocols involving 67 Gallium-Citrate and 18F-FDG

Lloyd secured $3,375 in internal research funding, including a 2012 New Staff Grant ($2,500) for oncological dose optimization and 2014 travel support ($875) for ANZSNM conference presentation. He currently co-supervises an Honours student on AI-driven cervical spine analysis and previously guided two projects on radiopharmaceutical quality control and concussion biomarkers.

His clinical-academic integration occurs through Hunter and New England Imaging Service collaborations, focusing on PET technological advancements and evidence-based protocol development.